Imatinib for chronic myeloid leukaemia: A NICE mess

Lancet

Volumn 358, Issue 9292, 2001, Pages 1478-

  Barbour, Virginia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB; PROTEIN TYROSINE KINASE;

BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG COST; DRUG EFFECT; HUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0035802758     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06571-0     Document Type: Note

References (5)

1. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia
2. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
3. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
4. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification